

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/43, 9/16, 9/20	A1	(11) International Publication Number: WO 99/11261 (43) International Publication Date: 11 March 1999 (11.03.99)
(21) International Application Number: PCT/EP98/05902 (22) International Filing Date: 27 August 1998 (27.08.98) (30) Priority Data: 97202651.2 29 August 1997 (29.08.97) EP (71) Applicant (<i>for all designated States except US</i>): GIST-BROCADES B.V. [NL/NL]; Wateringseweg 1, P.O. Box 1, NL-2600 MA DELFT (NL). (72) Inventor; and (75) Inventor/Applicant (<i>for US only</i>): GROENENDAAL, Jan, Willem [NL/NL]; Koorenmarkt 4, NL-2611 EE Delft (NL). (74) Agents: VISSER-LUIRINK, Gesina et al.; Gist-Brocades B.V., Patents and Trademarks Dept. (994-0760), Water- ingseweg 1, P.O. Box 1, NL-2600 MA Delft (NL).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: GRANULES FREE OF EXCIPIENTS (57) Abstract Granules free of excipients suitable for all pharmaceutical formulations have been provided for. Also a process to prepare said granules by employing a sieving device preferably comprising an air jet system has been provided for.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

GRANULES FREE OF EXCIPIENTS

The present invention relates to granules free of excipients and a
5 process to prepare the same.

Technical background and field of invention

It is generally known that crystalline antibiotic powder itself is not
10 suitable for the manufacturing of tablets and capsules containing oral grade
antibiotics such as penicillins or cephalosporins because the crystalline
material has no satisfactory flowability and density so that controlled dosage
per tablet or capsule is not guaranteed. Therefore, normally a granulate is
produced first by mixing the crystalline product (1-30 μm) with a small
15 amount of organic solvent (e.g. alcohol and/or water). It is preferred then to
admix other components as binders (e.g. PVP) and fillers (e.g. lactose) for
obtainment of granulates with satisfactory particle size distribution and
strength. However, it will not be possible to achieve a high dosage per tablet
unless relatively large tablets are made.

20 The granulation process generally takes place in a high shear mixer
granulator by which dense particles of a suitable particle size distribution are
produced. After the granulation process the material (particles of
approximately 400-500 μm average diameter) is dried. It is found that while
using only water as binding agent (i.e. no alcohol, no further binding agents)
25 the batch-wise operated high shear granulators can not give a satisfactory
particle size distribution while excessive fouling of the apparatus occurs.

Difficulties one may encounter by using wet granulation are:

- decomposition of β -lactam antibiotics because of use of water and/or organic
solvents combined with elevated temperature during granulation,
- 30 - the use of organic solvents is restricted by governmental rules concerning
environmental protection,

- the process is labour intensive, expensive and time consuming because of the large number of processing steps like mixing, granulating, wet sieving, drying etc.,

- a lot of energy is needed to dry the wet granules,

5 - granules produced by wet granulation are rather porous, high bulk volumes are not or difficult to reach with the consequence that high dosages in gelatin capsules are often not possible,

- binder dissolved in a binder solution or dry mixed with the compound to be granulated can give problems with a homogeneous distribution because of
10 their sticking nature with as result an inhomogeneous composition which can cause differences in dissolution and/or tablet hardness between dosage forms of one batch and therefore differences in bioavailability,

- variable "residual free water content" is added to the quality control analysis.

Difficulties one may encounter by using dry granulation are:

15 - a lot of dust is produced during the slugging or roller compaction process and in some cases, for example such as amoxicillin, this dust sticks to the coarser particles and can not be separated by currently applied vibrating sieves,

- dust may deteriorate the flow properties of granules, which inadequate flow
20 properties result in a larger weight variation of the dosage forms,

- dust is also responsible for air born β -lactam antibiotics particles which can cause allergic reaction,

- over compaction of initial granules gives a lower dissolution rate,

- possible over lubrication coupled with hydrophobisation due to use of a too
25 high amount of hydrophobic lubricant and hydrophobisation decreases the dissolution rate.

In German patent application DE 2251250, a process for relatively small tablets containing a high amount of antibiotic using a granulate prepared with a small (5-15%) amount of excipients (e.g. crystalline cellulose, binder,
30 talc) has been described. European patent EP 281200 describes a pharmaceutical granulate comprising 35-45 wt% microcrystalline cellulose

prepared by wet granulation, which granulate disintegrates quickly when immersed in water. Also, in PCT applications WO 9116893 and WO 9219227, for example, the antibiotic has been described to be mixed with excipients (e.g. an effervescent couple of excipients or intra-granular disintegrant, flavour, magnesium stearate) for granulation using slugging or a roller compactor for compacting. Thereafter, the granules have been sieved to the desired particle size and finer material is recycled to the compaction process. In PCT application WO 9528927, a pharmaceutical tablet formulation having a structure comprising compacted granules of amoxicillin and clavulanate in a weight ratio of 6:1 to 8:1, excipients and a coating of polymers has been described.

Surprisingly it is found that granules without any excipients can be prepared. These have nowhere been described or suggested in the prior art.

Summary of the invention

The present invention provides granules being free of excipients, for instance antibiotic and antihypercholesterolemic ones and preferably also substantially free of solvents. These granules are of a particle size between about 50 μm and 1500 μm , preferably between about 125 μm and 1000 μm .

Examples of antibiotic granules are those of penicillins, cephalosporins, tetracyclines and macrolides. Examples of penicillins are preferably amoxicillin, ampicillin, penicillin V, oxacillin, cloxacillin, flucloxacillin, dicloxacillin and pharmaceutically acceptable salts thereof, preferably potassium salt of penicillin V, sodium salt of cloxacillin, sodium salt of flucloxacillin and sodium salt of dicloxacillin. Examples of cephalosporins are preferably cephalexin, cefaclor, cefadroxil and cephadrine. Examples of tetracyclines are tetracycline, chlorotetracycline, oxytetracycline, doxycycline, minocycline, demeclocycline and acid salts thereof, preferably the HCl salts. Examples of macrolides are preferably erythromycin, clarithromycin, roxithromycin, azithromycin and stearates, estolates, propionates, ethylsuccinates thereof.

Examples of antihypercholesterolemic compounds are lovastatin, simvastatin and pravastatin.

Furthermore, a process to prepare said granulates has been provided for. The process comprises of feeding, for example, an antibiotic powder
5 corresponding to said granules to a roller compactor to produce compacts, followed by milling to give granules. These granules are, then, sieved with a sieving device to separate the granules from fine particles with a size of $<150\text{ }\mu\text{m}$, preferably $<125\text{ }\mu\text{m}$. The sieving device preferably comprises an air jet system. The fine particles are optionally recirculated to the roller
10 compactor.

The granules, prepared according to the present invention, are suitable to prepare oral dosage forms such as tablets, capsules, syrups, sachets, dry instant or ready to use and multiple or single dose. According to the another embodiment of the invention, the oral dosage form, comprising granules free
15 of excipients also contain a β -lactamase inhibitor such as potassium clavulanate, preferably in granule form. Said granules can also be used in Dose Sipping devices.

Detailed description of the invention

The granulation method, wherein the use of excipients has been avoided, consists of dry granulation by using compaction forces to build up agglomerates. This may be performed by slugging or roller compacting. The compacts are milled and, then, sieved with a sieving device. The separation of
25 fine particles from coarse granules may be carried out by a dry sieving or wet sieving procedure.

During dry sieving, the milled compacts are placed on the sieve and air is blown through the bed of milled compacts to separate the granules from the fine particles. The sieving device comprises preferably an air jet system.
30 Furthermore, the sieving device can be coupled directly to the roller compactor or stand separately from the same.

The application of this granulation method results in granules of penicillins, cephalosporins, tetracyclines, macrolides and antihypercholesterol compounds with a satisfactory particle size distribution, viz. between 50 μm and 1500 μm , preferably between 125 μ and 1000 μm . Moreover, these granules are preferably substantially free of organic solvents and/or water, because during the process of compaction, use of these solvents are usually avoided. The only traces of solvent(s) that may be present in the said granules are either already present in the starting compound or result from wet sieving operation.

For example, a certain amount of antibiotic powder to be granulated, for instance amoxicillin trihydrate, is fed to a roller compactor. The compact materials are milled and, thereafter, sieved by using an air jet system. The sieving device is coupled directly to the roller compactor in order to avoid extra steps or stands separately. The fine particles, preferably the material < 125 μm , are recycled to the roller compacting process.

The granules free of excipients can be used for all formulations to produce chew, swallow, disperse, effervescent or normal tablets of all sizes, forms and weights, also to fill hard gelatin capsules and to formulate dry syrups and for administering drugs with the help of a dose sipping device. These granules can also be used, for instance, in a pharmaceutical composition as a tablet of amoxicillin trihydrate produced from granules of amoxicillin trihydrate and potassium clavulanate (in ratio of 1-20:1 as, for example, described in European patent EP 49061 and International patent application WO 9709042) as a powder or in granule form.

To produce tablets, only excipients have to mixed with the granules and tablets can be pressed. To fill hard gelatin capsules no excipients are necessary, the granules can directly be filled into capsules or when fast running capsules filling machines are used, some lubricant like magnesium stearate can be mixed with the granules to facilitate the filling process.

To formulate dry oral syrups, flavours, bulking agents such as sugars and preservatives are often used. These excipients are mixed with the

granules and bottles are filled thereof. Optionally a premix of excipients is prepared and filled into bottles after which the granules are added separately.

For Dose Sipping Devices, for example, the granules can be placed over a support in a tube having a liquid inlet end and a liquid outlet end; excipients
5 can also be placed over the support, together with the drug granules. Oral administration of therapeutical agents with the help of a Dose Sipping Device has been described in European patent application EP 383503.

The preparation of granules without the use of excipients, according to the present invention, has the following advantages over the existing
10 methods:

- economy in labour, time, equipment, energy and space,
- it eliminates problems in granulation processes due to heat and moisture,
- it allows for disintegration of dosage forms into primary drug particles followed by a high dissolution rate because no binders have been used,
- 15 - the resulting granulates show excellent flow properties and almost no dust at all,
- the resulting granulates containing antibiotics or antihypercholesterol compounds show all-around technological properties for the production of all oral dosage forms like tablets, capsules, syrups, sachets, dry instant or ready
20 to use, multi dose or single dose and for dose sipping devices,
- as not any excipient is used for the production, these all-round granulates provide a large flexibility.

Also the preparation of a pharmaceutical composition of granules of β -lactams, for instance amoxicillin trihydrate and a β -lactam inhibitor, for
25 instance clavulanic acid or a pharmaceutical acceptable salt thereof, or sulbactam, preferably in the granule form, have been provided for. The granules of the β -lactam inhibitor optionally contain an excipient.

The invention will now be described with reference to the following examples, which are not to be constructed as being limited to the invention,
30 and are provided purely for illustrative purposes.

Preparation 1**Production of amoxicillin granulate by roller compacting using conventional vibrating sieving.**

5

Amoxicillin trihydrate powder was fed to a Fitzpatrick roller compacter type Chilsonator 4L X 10D. The used rolls had a diameter of 25.4 cm and a roll wide of 10.2 cm, the roll surface was sinus waved grooved, the roll gap was 3.1 mm. The roll speed was 11 rpm, the horizontal feeder speed was 17 rpm, the vertical feeder speed 450 rpm and the applied roll pressure 1100 psi.

The compacts were milled using a Fitzmill type DAS 06 equipped with type 425 blades adjusted with the sharp ends forward, the mill speed was 1500 rpm and the used screen had apertures of 2 mm. The milled material was sieved using a Midwestern vibrating sieve with apertures of 150 μm .

The material $> 150 \mu\text{m}$, collected from the 150 μm sieve was the final product. The fines $< 150 \mu\text{m}$ were recycled from the receiver to the roller compacting process.

Example 1**Production of amoxicillin granulate by roller compacting using air sieving.**

The same roller compacting procedure as mentioned under example 1 was performed except for sieving the milled material.

Instead of a vibrating sieve, a Minox sieve type MTS 1200 equipped with an air jet system was used. The sieve applied had a diameter of 120 cm and apertures of 150 μm . The air was escaping upwards from a rotating perforated blade fixed horizontal under the sieve. By this action the fine particles were blown off from the coarse particles and sucked downwards through the sieve to the receiver by the action of an under pressure.

The fines $< 150 \mu\text{m}$ were recycled from the receiver to the roller compacting process. The material $> 150 \mu\text{m}$, collected from the $150 \mu\text{m}$ sieve, was the final product.

Example 2

Separation of fines from coarse amoxicillin granulate particles of preparation 1 for analytical purpose.

The following three analytical sieving methods were used to separate fine from coarse particles amoxicillin granulate:

Vibrating sieve:

Sieves with a diameter of 20 cm, apertures of 125, 250 and $1000 \mu\text{m}$ and known weight were stacked with the $1000 \mu\text{m}$ sieve on top and a collecting pan with known weight on the bottom. 80 g of amoxicillin granulate was weighed and added to the top sieve. The sieving machine, a Retch type Vibro, was turned on for 10 minutes using a vibration power setting of 80. The amounts of amoxicillin were determined by weighing the sieves and collecting pan.

Wet sieve:

Sieves with a diameter of 75 mm, apertures of 125, 250 and $1000 \mu\text{m}$ and known weight were stacked with the $1000 \mu\text{m}$ sieve on top and a collecting pan on the bottom. 3 g of amoxicillin granulate was weighed and added to the top sieve with the aid of n-hexane which is a non-solvent for amoxicillin. Applying small amounts of a total of 200 ml n-hexane the top sieve was flushed. The n-hexane suspension in the collecting pan was filtered with the aid of a filter paper of known weight. The sieves and filter were dried in a ventilation cabinet. The amounts of amoxicillin were determined by weighing the sieves and filter.

Air sieve:

A sieve with a diameter of 20 cm, known weight and apertures of $125 \mu\text{m}$ was put on a Hosokawa Alpine air sieve type 200 LS-N, 20 g amoxicillin

granulate was weighed and put on the sieve. The air sieve was activated during 3 minutes, whereafter the amount of amoxicillin was determined by weighing the sieve.

The test was repeated with a 250 and 1000 μm sieve.

5

Table 1 Results of three sieve test methods applied on amoxicillin granulate of preparation 1

sieve method	> 1000 μm	< 1000 μm and > 250 μm	< 250 μm and > 125 μm	< 125 μm
vibrating sieve	11.0%	78.7%	78.7%	0.7%
wet sieve	9.4%	58.4%	6.2%	25.9%
air sieve	9.1%	58.3%	5.8%	26.0%

10

Using the vibrating sieve method it is not possible to separate the fine from the coarse particles. The air sieving method, which gives comparable results with the wet sieving one, is very reliable.

15

These results show clearly that amoxicillin granulates produced with the conventional roller compacting process contain a lot of fine particles, which can not be separated from the coarse particles by a conventional vibrating sieving method.

20

Example 3

Flowability of amoxicillin granulate of preparation 1.

The following two analytical methods were used to determine the flowability of the amoxicillin granulate:

25

1. Flowability funnels after Lerk (from Pharmaceutical Technology, Post-Academic Course in 1977):

Five Funnels, with varying diameter of 2.5 - 5 - 8 - 12 and 18 mm, were positioned vertical with the small opening downwards. The funnel with the smallest opening was filled with amoxicillin granulate while the opening

30

was closed with a finger. The flowability of the granulate was observed when the finger was removed. If the granulate did not flow through the funnel the test was repeated with a funnel with a one step larger opening. The flowability of the granulate was determined by a smooth flow through the funnel with the size of the smallest opening.

The class of flowability was determined using the classification of table 2.

Table 2 Flowability classification using different funnel openings according to Lerk

class	diameter funnel	flowability
1	2.5 mm	excellent
2	5 mm	good
3	8 mm	amply sufficient
4	12 mm	just sufficient
5	18 mm	poor

The amoxicillin granulate of example 1 did not flow through the funnel with a diameter of 18 mm so this material shows a poor flowability.

2. Compressibility or Hausner ratio (see The Theory and Practice of Industrial Pharmacy, 3rd edition, 1986 page 184 and Powder Testing Guide, 1987 page 91 - 93):

A graduated cylinder of 250 ml was filled carefully with amoxicillin granulate up to the 250 ml mark, the weight of the amoxicillin was determined and the loose bulk density was calculated in g/ml.

The cylinder was tapped using an Engelsmann Volumeter until the volume did not change more than 2 ml after 100 taps, the decreased volume was determined and the tapped bulk density was calculated in g/ml.

The compressibility was calculated according to the following formula:

$$\frac{(\text{tapped bulk density} - \text{loose bulk density}) \times 100\%}{\text{tapped bulk density}}$$

5 The Hausner ratio was calculated according to the following formula:

$$\frac{\text{tapped bulk density}}{\text{loose bulk density}}$$

10

The class of flowability was determined using the classification of table 3.

Table 3 Flowability classification using loose and tapped bulk density

15

compressibility	Hausner ratio	flowability
5 - 15%	1.05 - 1.18	excellent
12 - 16%	1.14 - 1.19	good
18 - 21%	1.22 - 1.27	fair - passable
23 - 35%	1.30 - 1.54	poor
33 - 38%	1.49 - 1.61	very poor
> 40%	> 1.67	very, very poor

20

The amoxicillin granulate of example 1 showed the following results:

- loose bulk density : 0.59 g/ml
- tapped bulk density : 0.84 g/ml
- 25 - compressibility : 30%
- Hausner ratio : 1.42.

These results indicate a poor flowability.

Example 4

30

Separation of fine from coarse amoxicillin granulate particles of example 1.

The air sieve method mentioned in example 2 was applied on amoxicillin particles.

The results are presented in table 4.

Table 4 Results air sieve test applied on amoxicillin granulate of example 2

sieve method	> 1000 μ m	< 1000 μ m and > 250 μ m	< 250 μ m and > 125 μ m	< 125 μ m
air sieve	0.1%	81.4%	14.7%	3.8%

Example 5

Flowability of amoxicillin granulate of example 1.

The flowability method using the funnels according to Lerk mentioned in example 3 was used. The amoxicillin granulate of example 1 did flow smoothly through the funnel with a diameter of 5 mm so this material showed a good flowability. The flowability method according to the compressibility / Hausner ratio measurement was used.

The amoxicillin granulate of example 1 showed the following results:

- loose bulk density: 0.52 g/ml
- tapped bulk density: 0.60 g/ml
- compressibility: 13%
- Hausner ratio: 1.15

These results also indicate a good flowability.

Example 6

Production of tablets containing amoxicillin granulate of example 1

2.15 kg of amoxicillin granulate (prepared from amoxicillin trihydrate according to example 1), 0.49 kg of microcrystalline cellulose (Avicel®) PH112 with a water activity of less than 0.2 at 25 °C) and 0.1 kg of hydrogenated vegetable oils (Lubritab®) were weighed and mixed in a Turbula mixer and

subsequently about 5000 tablets were produced on Korsch KO1 excenter tablet press equipped with flat 12 mm punches. The characteristics of the tablets were:

diameter 12 mm; thickness 4.3 mm; weight variation according to U.S. Pharmacopoeia XXIII 1994, The United States Pharmacopoeial Convention Inc. Rockville, MD, USA; hardness between 100 and 130 N, disintegration 30 seconds in water of 20 °C.; dissolution more than 85% of the labelled amount of amoxicillin dissolves within 30 minutes by using the method as described in U.S. Pharmacopoeia XXIII 1994, The United States Pharmacopoeial Convention Inc. Rockville MD, USA.

Example 7

Production of four different formulations of tablets containing amoxicillin granulate of example 1

Compositions of the tablet formulations

Materials	Formulations (mg per tablet)			
	A	B	C	D
Amoxicillin granules from example 2	287.5	287.5	287.5	287.5
Lactose anhydrous (Pharmatose DCL 21)	725.0			
Lactose monohydrate (Pharmatose DCL 15)		725.0		
Dibasic Calcium Phosphate dihydrate (Emcompress)			725.0	
Microcrystalline cellulose (Avicel PH 112)				975.0
Maize starch B	250.0	250.0	250.0	
Magnesium stearate	20.0	20.0	20.0	20.0

Preparation of the tablets

Amoxicillin granules and the excipients (except magnesium stearate) were weighed according to the above compositions and mixed during 5 minutes in a Turbula mixer, the total weight of the materials was about

100 g. Magnesium stearate, which was previously sieved through 90 μm , was added and mixed during 1 minute.

Finally, tablets were pressed using a Korsch EKO excenter tablet press equipped with flat punches with a diameter of 12 mm.

5

Analytical results of tablet tests (between brackets the standard deviation)

10

Formulation	Weight [mg] (N = 20)	Thickness [mm] (N = 10)	Hardness [N] (N = 10)	Friability after 100 revolutions [w/w%] (20 tablets)	Disintegration in tap water without stirring [sec] (N = 3)	Dissolution after 30 min. in 900 ml water of 37°C using paddles at 75 rpm (N = 4)
A	411.4 $\pm$ 12.9	3.149 $\pm$ 0.019	104.9 $\pm$ 26.3	0.46%	130	100% *
B	397.6 $\pm$ 3.9	3.149 $\pm$ 0.019	123.7 $\pm$ 21.3	0.38%	70	100% *
C	400.8 $\pm$ 4.4	2.842 $\pm$ 0.018	114.4 $\pm$ 15.9	0.44%	57	100% *
D	392.1 $\pm$ 5.9	3.106 $\pm$ 0.016	120.8 $\pm$ 15.7	0.17%	50	100% *

15

* % released of total amount of amoxicillin in tablet

Example 8

Preparation of capsules containing amoxicillin granules

20

Amoxicillin granulate (prepared from amoxicillin trihydrate according to example 1) was filled into hard gelatine capsules on a Robert Bosch GKF 1200 S capsule filling machine using continuous motion with tamping and a speed of about 65,000 capsules per hour.

25

Example 9

Preparation of tablets containing amoxicillin granules and potassium clavulanate granules

30

During the preparation procedures, the temperature was between 20 and 25 °C and the relative humidity < 20%.

Amoxicillin granules were prepared according to example 1, the water activity of the granules was less than 0.2 at 25 °C, which was obtained by drying the granules during 30 minutes at 40 °C and reduced pressure in a rotating mixer.

5 Potassium clavulanate granules were prepared as follows:

Potassium clavulanate powder with a water activity of less than 0.2 at 25 °C was mixed with microcrystalline cellulose (Avicel® PH112 with a water activity of less than 0.2 at 25 °C). The mixture was then fed to a roller compactor. The produced compacts were milled with an oscillating Frewitt
10 sieve equipped with a screen with 1000 µm apertures.

The milled material was classified using a vibration sieve equipped with a 420 µm screen on top and a 150 µm screen equipped with an air jet system on the bottom. The material coming from the top of the 420 µm screen and from the top of the 150 µm screen was transferred to a batch mixer, the fine
15 material from the bottom of the sieve was transferred back to the roller compactor. After homogenisation of the granules in the batch mixer, the granules were ready for further processing into tablets.

The tablets were prepared as follows:

Potassium granulate granules (1.52 kg) with a potency of 41.1%
20 clavulanic acid, amoxicillin trihydrate granules (2.925 kg) with a potency of 85.5% amoxicillin, 0.047 kg magnesium stearate, and 0.162 kg microcrystalline cellulose (Avicel® PH112 with a water activity of less than 0.2 at 25 °C). were mixed.

Tablets were pressed using a Korsch EKO excenter tablet press with the
25 following characteristics:
diameter 18 mm, weight 950 mg, thickness 6 mm, hardness between 110 and 150 N, disintegration in water of 20 °C in less than 60 seconds, dissolution of the labelled amount of amoxicillin within 30 minutes by using the method as described in the U.S. Pharmacopoeia XXIII 1994, The United
30 States Pharmacopoeial Convention Inc. Rockville MD, USA.

CLAIMS

1. Granules free of excipients.

2. Pharmaceutical granules according to claim 1.

3. Antibiotic and antihypercholesterolemic granules according to claim 2.

4. Granules according to any one of the claims 1-3 wherein the granules are substantially free of solvents.

5. Granules according to anyone of the claims 1-4 wherein granules have a particle size between 50 and 1500 μm , preferably between 125 and 1000 μm .

6. Granules according to anyone of the claims 1-5 wherein the granules are granules of β -lactams.

7. Granules according to claim 6 wherein the granules are granules of penicillins, preferably amoxicillin, ampicillin, penicillin V, oxacillin, cloxacillin, flucloxacillin, dicloxacillin and pharmaceutically acceptable salts thereof.

8. Granules according to claim 7 wherein the granules are granules of potassium salt of penicillin V, sodium salt of cloxacillin, sodium salt of flucloxacillin and sodium salt of dicloxacillin.

9. Granules according to claim 6 wherein the granules are granules of cephalosporins, preferably cephalexin, cefaclor, cefadroxil and cephradine.

10. Granules according to anyone of the claims 1-5 wherein the granules are granules of tetracyclines, preferably tetracycline, chlortetracycline, oxytetracycline, doxycycline, minocycline, demeclocycline and acid salts thereof, preferably the HCl salt.

5

11. Granules according to anyone of the claims 1-5 wherein the granules are granules of macrolides, preferably erythromycin, clarithromycin, roxithromycin, azithromycin and stearates, estolates, propionates and ethylsuccinates thereof.

10

12. Granules according to anyone of the claims 1-5 wherein the granules are granules of lovastatin, simvastatin and pravastatin.

13. A process for the preparation of granules defined in anyone of the claims 1-12, comprising:

15

- feeding a powder to be granulated to a roller compactor producing compacts,
- milling the compacts to produce granules,
- sieving the granules with a sieving device optionally coupled to the roller compactor to separate the granulates from fine particles of $<150\text{ }\mu\text{m}$, preferably $<125\text{ }\mu\text{m}$,
- optionally recirculating said fine particles to the roller compactor.

20

14. A process according to claim 13 wherein the sieving device comprises an air jet system.

25

15. A process according to claim 14, wherein the sieving device stands separately from the roller compactor.

16. Oral dosage forms as tablets, capsules, syrups, sachets, dry instant or ready to use, multiple or single dose produced from granules as defined in anyone of the claims 1-12.

30

17. Oral delivery form produced from granules as defined in anyone of the claims 1-12 for using as a Dose Sipping device.

5 18. Pharmaceutical composition comprising granules as defined in claim 7 mixed with a β -lactamase inhibitor.

 19. Pharmaceutical composition according to claim 18 comprising granules of amoxicillin trihydrate mixed with potassium clavulanate.

10

 20. Pharmaceutical composition according to claim 19 comprising granules of amoxicillin trihydrate mixed with granules of potassium clavulanate.

15

INTERNATIONAL SEARCH REPORT

In tional Application No

PCT/EP 98/05902

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/43 A61K9/16 A61K9/20

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 414 115 A (BASF) 27 February 1991 see claims see examples see page 2, line 41 - line 45 see page 3, line 1 - line 3 ---	1, 2, 4, 5, 13
A	DE 22 51 250 A (HOECHST) 2 May 1974 cited in the application see claims see examples ---	1-20
A	WO 92 19227 A (SMITHKLINE BEECHAM) 12 November 1992 cited in the application see claims see example 1 --- -/--	1-20



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

3 December 1998

Date of mailing of the international search report

09/12/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Scarponi, U

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/05902

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 281 200 A (GIST-BROCADES) 7 September 1988 cited in the application see the whole document ----	1-20
A	EP 0 194 880 A (SANKYO) 17 September 1986 see the whole document ----	1-20
A	WO 91 16893 A (BEECHAM) 14 November 1991 cited in the application see the whole document ----	1-20
A	WO 95 28927 A (SMITHKLINE BEECHAM) 2 November 1995 cited in the application see the whole document ----	1-20
P,X	WO 97 33564 A (BIOCHEMIE GESELLSCHAFT MBH,AT) 18 September 1997 see the whole document -----	1-9, 16-20

INTERNATIONAL SEARCH REPORT

Information on patent family members

In: International Application No

PCT/EP 98/05902

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 414115	A	27-02-1991	DE 3927810 A	28-02-1991
			CA 2023815 A	24-02-1991
			DK 414115 T	13-04-1993
			JP 2081231 C	09-08-1996
			JP 3099014 A	24-04-1991
			JP 7119172 B	20-12-1995
			US 5137732 A	11-08-1992
DE 2251250	A	02-05-1974	AT 338430 B	25-08-1977
			AT 884973 A	15-12-1976
			AU 6151373 A	17-04-1975
			BE 806294 A	19-04-1974
			CH 608964 A	15-02-1979
			DK 143436 B	24-08-1981
			FR 2247208 A	09-05-1975
			GB 1451804 A	06-10-1976
			NL 7314085 A	23-04-1974
			SE 416176 B	08-12-1980
			ZA 7308100 A	28-05-1975
WO 9219227	A	12-11-1992	AP 328 A	23-03-1994
			AU 659836 B	01-06-1995
			AU 1649892 A	21-12-1992
			BR 9205948 A	08-11-1994
			CA 2102630 A	09-11-1992
			CN 1067577 A	06-01-1993
			CZ 9302379 A	16-03-1994
			EP 0585252 A	09-03-1994
			EP 0783889 A	16-07-1997
			EP 0787487 A	06-08-1997
			FI 934914 A	05-11-1993
			HU 67020 A	30-01-1995
			IL 101795 A	16-10-1996
			JP 6507396 T	25-08-1994
			MX 9202118 A	01-03-1993
			NO 934009 A	05-11-1993
			NZ 242625 A	26-08-1994
			PT 100458 A	31-08-1993
			SK 112793 A	08-06-1994
EP 281200	A	07-09-1988	AU 603870 B	29-11-1990
			AU 1252088 A	01-09-1988
			CA 1338467 A	23-07-1996
			CN 1036763 B	24-12-1997
			DE 3887179 D	03-03-1994
			DE 3887179 T	16-06-1994
			DK 108888 A	03-09-1988
			ES 2061623 T	16-12-1994
			FI 880928 A,B,	03-09-1988
			IE 70907 B	15-01-1997
			JP 63301820 A	08-12-1988
			KR 9609182 B	16-07-1996
			NO 174996 B	09-05-1994
			PT 86870 B	29-05-1992
			US 4950484 A	21-08-1990
EP 194880	A	17-09-1986	JP 1871914 C	26-09-1994
			JP 62000038 A	06-01-1987

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/05902

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9116893 A	14-11-1991	AT 139694 T	15-07-1996
		AU 657476 B	16-03-1995
		AU 7778391 A	27-11-1991
		CA 2081349 A	28-10-1991
		DE 69120536 D	01-08-1996
		DE 69120536 T	23-01-1997
		DK 528846 T	29-07-1996
		EP 0528846 A	03-03-1993
		ES 2089212 T	01-10-1996
		GR 3020749 T	30-11-1996
		PT 97491 A,B	31-01-1992
		US 5670170 A	23-09-1997
WO 9528927 A	02-11-1995	AP 564 A	21-11-1996
		AU 684949 B	08-01-1998
		AU 2406895 A	16-11-1995
		BG 100933 A	31-07-1997
		BR 9507502 A	02-09-1997
		CA 2188496 A	02-11-1995
		CN 1149829 A	14-05-1997
		CZ 9603090 A	16-04-1997
		EP 0758235 A	19-02-1997
		EP 0761218 A	12-03-1997
		FI 964249 A	22-10-1996
		HU 76335 A	28-08-1997
		JP 9512027 T	02-12-1997
		NO 964488 A	17-12-1996
		NZ 285080 A	27-05-1998
		PL 316966 A	03-03-1997
		SK 135496 A	07-05-1997
		ZA 9503236 A	27-12-1995
WO 9733564 A	18-09-1997	AU 2156097 A	01-10-1997